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Abstract
Background: Visfatin, a adipocytokine with insulin-mimetic effect, plays a role in endothelial angiogenesis.
Hyperbaric oxygen (HBO) has been used in medical practice. However, the molecular mechanism of beneficial
effects of HBO is poorly understood. We sought to investigate the cellular and molecular mechanisms of regulation
of visfatin by HBO in human coronary arterial endothelial cells (CAECs).
Methods: Human CAECs were exposed to 2.5 atmosphere absolute (ATA) of oxygen in a hyperbaric chamber.
Western blot, real-time polymerase chain reaction, and promoter activity assay were performed. In vitro glucose
uptake and tube formation was detected.
Results: Visfatin protein (2.55-fold) and mRNA (2.53-fold) expression were significantly increased after exposure to
2.5 ATA HBO for 4 to 6 h. Addition of SP600125 and JNK siRNA 30 min before HBO inhibited the induction of
visfatin protein. HBO also significantly increased DNA-protein binding activity of AP-1 and visfatin promoter activity.
Addition of SP600125 and TNF-a monoclonal antibody 30 min before HBO abolished the DNA-protein binding
activity and visfatin promoter activity induced by HBO. HBO significantly increased secretion of TNF-a from
cultured human CAECs. Exogenous addition of TNF-a significantly increased visfatin protein expression while TNF-a
antibody and TNF-a receptor antibody blocked the induction of visfatin protein expression induced by HBO. HBO
increased glucose uptake in human CAECs as HBO and visfatin siRNA and TNF-a antibody attenuated the glucose
uptake induced by HBO. HBO significantly increased the tube formation of human CAECs while visfatin siRNA, TNF-
a antibody inhibited the tube formation induced by HBO.
Conclusions: HBO activates visfatin expression in cultured human CAECs. HBO-induced visfatin is mediated by
TNF-a and at least in part through JNK pathway.
Background
Visceral fat accumulation has been shown to play crucial
roles in the development of cardiovascular disease as
well as the development of obesity-related disorders [1].
Recent evidences show that fat tissue is an active endo-
crine organ producing “adipocytokines”,h o r m o n e st h a t
influence a diverse array of processes including appetite
and energy balance, immunity, insulin sensitivity,
haemostasis, blood pressure, lipid metabolism and
angiogenesis, all factors which can impact cardiovascular
disease [2]. The recently discovered adipocytokine, visfa-
tin, also known as pre-B cell colony-enhancing factor,
has been demonstrated to mimic the glucose-lowering
effect of insulin and improve insulin sensitivity [3].
However, the effects of visfatin are not restricted to glu-
cose homeostasis. Visfatin was upregulated by hypoxia
in adipocytes and in breast cancer cell through hypoxia-
inducible factor-1 [4,5]. Recently, visfatin was shown to
play a role in endothelial angiogenesis by activation of
fibroblast growth factor2, signal transducer and activator
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any medium, provided the original work is properly cited.of transcription 3, and vascular endothelial growth fac-
tor and matrix metalloproteinase [6-9]. Several factors
that could regulate visfatin synthesis have been identi-
fied [10,11]. Overall, visfatin is a cytokine with various
functions [12].
Hyperbaric oxygen (HBO) therapy provides a signifi-
cant increase in oxygen content in the hypoperfused tis-
sue and the elevation in oxygen content in the hypoxic
tissue induces powerful positive changes in ischemic
repair process [13]. Therefore, HBO is successfully used
for the treatment of a variety of clinical conditions [14].
HBO therapy promotes wound healing by directly enhan-
cing fibroblastic replication, collagen synthesis, and the
process of neovascularization in ischemic tissue [15].
Because of the emerging concept of coronary artery
endothelial cells (CAECs) in the progress of angiogen-
esis and no data have been presented to verify the effect
of HBO on the regulation of visfatin in human CAEC.
Therefore we hypothesize that HBO activates a proin-
flammatory response mediated through a specific tran-
scription factor, and downstream effects of this
activation increased the expression of visfatin. Therefore,
we sought to investigate the cellular and molecular
mechanisms of regulation of visfatin by HBO in human
CAECs. The induction of visfatin in human CAECs by
HBO may elucidate the mechanisms responsible for the
therapeutic effect of HBO.
Methods
Primary human coronary artery endothelial cells (CAECs)
culture
Human coronary artery endothelial cells (CAECs) were
originally obtained from PromoCell GmbH (Heidelberg,
Germany). The cells were cultured in endothelial cell
growth medium MV supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin at 37°C in a humidified atmosphere of 5% CO2
in air. Cells were grown to 80-90% confluence in 10
cm
2 culture dishes and were sub-cultured in the ratio of
1:2.
HBO treatment
For HBO treatment, cells were exposed to 2.5 ATA
(atmosphere absolute) of oxygen (98% oxygen plus 2%
CO2) in a hyperbaric chamber for 2 to 8 h at 37°C. The
small hyperbaric chamber was put in a temperature-
controlled (37°C) incubator (Additional file 1, Figure
S1). The oxygen tension was chosen based on the
human treatment protocols [16]. For the inhibition of
signal pathways, cells were pretreated with inhibitors for
30 min, and then exposed to HBO without changing
medium. SP600125 (20 μM, CALBIOCHEM
®,S a n
Diego, CA) is a potent, cell-permeable, selective, and
reversible inhibitor of c-Jun N-terminal kinase (JNK).
SB203580 (3 μM, CALBIOCHEM
®) is a highly specific,
cell permeable inhibitor of p38 kinase. PD98059 (50 μM,
CALBIOCHEM
®) is a specific and potent inhibitor of
extracellular-signal-regulated kinase (ERK) kinase. Wort-
mannin ((5 nM, Sigma Chemical, St. Louis, MO, USA) is
a phosphatidylinositiol-3 (PI-3) kinase inhibitor.
Western blot analysis
Cells under HBO were harvested by scraping and then
centrifuged (300 × g) for 10 minutes at 4°C. The pellet
was resuspended and homogenized in a Lysis Buffer
(Promega Corp., Madison, WI, USA), centrifuging at
10,600 × g for 20 minutes. Bio-Rad Protein Assay was
used for the measure of protein content. Equal amounts
of protein (15 μg) were loaded into a 12.5% SDS-polya-
crylamide minigel, followed by electrophoresis. Proteins
were electroblotted onto nitrocellulose. The blots were
incubated overnight in Tris-buffered saline containing
5% milk to block nonspecific binding of the antibody.
Proteins of interest were revealed with specific antibo-
dies as indicated (1:1000 dilution) for 1 hour at room
temperature followed by incubation with a 1:5000 dilu-
tion of horseradish peroxidase-conjugated polyclonal
anti-rabbit antibody for 1 h at room temperature. The
membrane was then detected with an enhanced chemi-
luminescence detection system (ECL, Amersham, Buck-
inghamshire, England). Equal protein loading of the
samples was further verified by staining mouse anti-
tubulin monoclonal antibody from Santa Cruz Biotech-
nology Inc. All Western blots were quantified using
densitometry.
RNA isolation and reverse transcription
Total RNA was isolated from cells using the single-step
acid guanidinium thiocyanate/phenol/chloroform extrac-
tion method. Total RNA (1 μg) was incubated with 200
U of Moloney-Murine Leukemia Virus reverse transcrip-
tase in a buffer containing a final concentration of 50
mmol/L Tris-Cl (pH 8.3), 75 mmol/L KCl, 3 mmol/
MgCl2, 20 U of RNase inhibitor, 1 μmol/L poly-dT oli-
gomer, and 0.5 mmol/L of each dNTP in a final volume
of 20 μL. The reaction mixture was incubated at 42°C
for 1 h and then at 94°C for 5 minutes to inactivate the
enzyme. A total of 80 μL of diethyl pyrocarbonate trea-
ted water was added to the reaction mixture before sto-
rage at -70°C.
Real-time quantitative PCR
A Lightcycler (Roche Diagnostic s, Mannheim, Ger-
many) was used for real -time PCR. cDNA was diluted
1i n1 0w i t hn u c l e a s e - f r e ew a t e r .2μLo ft h es o l u t i o n
was used for the Lightcycler SYBR -Green mastermix
(Roche Diagnostics): 0.5 μmol/L primer, 5 mmol/L mag-
nesium chloride, and 2 μL Master SYBR-Green in
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initial denaturation phase for specific gene was 5 min at
95°C followed by an amplification phase as detailed
below: denaturation at 95°C for 10 sec; annealing at 63°
C for 7 sec; elongation at 72°C for 8 sec; detection at
79°C and for 45 cycles. Amplification, fluorescence
detection, and post -processing calculation were per-
formed using the Lightcycler apparatus. Individual PCR
products were analyzed for DNA sequence to confirm
the purity of the product.
Promoter activity assay
Visfatin gene was amplified with forward primer,
CCACCGACTCGTACAAG and reverse primer, GTG
AGCCAGTAGCACTC. The amplified product was
digested with MluI and BglII restriction enzymes and
ligated into pGL3-basic luciferase plasmid vector (Pro-
mega) digested with the same enzymes. Site-specific
mutations were confirmed by DNA sequencing. Plas-
mids were transfected into human CAECs using a low
pressure-accelerated gene gun (Bioware Technologies,
Taipei, Taiwan) essentially following the protocol from
the manufacturer. Test plasmid at 2 μg and control plas-
mid (pGL4-Renilla luciferase) 0.02 μg was co-transfected
with gene gun in each well, and then replaced by nor-
mal culture medium. Following 6 hours of HBO, cell
extracts were prepared using Dual-Luciferase Reporter
Assay System (Promega) and measured for dual lucifer-
ase activity by luminometer (Turner Designs).
Electrophoretic mobility shift assay (EMSA)
Nuclear protein concentrations from cells were deter-
mined by Bio-rad protein assay. Consensus and control
oligonucleotides (Santa Cruz Biotechnology Inc.) were
labeled by polynucleotides kinase incorporation of
[g
32P]-ATP. After the oligonucleotide was radiolabeled,
the nuclear extracts (4 μg of protein in 2 μl of nuclear
extract) were mixed with 20 pmol of the appropriate
[g
32P]-ATP -labeled consensus or mutant oligonucleo-
tide in a total volume of 20 μl for 30 min at room tem-
perature. The samples were then resolved on a 4%
polyacrylamide gel. Gels were dried and imaged by auto-
radiography. Controls were performed in each case with
mutant oligonucleotides or cold oligonucleotides to
compete with labeled sequences.
Measurement of TNF-a concentration by enzyme-linked
immunosorbent assay
Conditioned medium from human CAECs subjected to
HBO and those from control cells were collected for TNF-
a measurement. The level of TNF-a was measured by a
quantitative sandwich enzyme immunoassay technique
(Amersham Pharmacia Biotech, Buckinghamshire, Eng-
land). The lowest limit of TNF-a ELISA kit was 5 pg/ml.
Capillary-like network formation Assay
Capillary-like network formation was performed in an
in vitro culture system. Matrigel 250 μL (BD Biosciences,
MA) was coated in a 24-well culture plate and allowed to
solidify (37°C, 1 hr). Human CAECs were cultured on a
Matrigel matrix and were exposed to 2.5 ATA of oxygen
(98% oxygen plus 2% CO2) in a hyperbaric chamber for 6
hrs at 37°C. After HBO treatment, cells were placed in a
humidified incubator for 16 hrs with an atmosphere of 5%
CO2 at 37°C. The capillary-like network formation was
observed with a phase-contrast microscope (Nikon, Tokyo).
Migration assay
The migration activity of human CAECs was deter-
mined using the growth factor-reduced Matrigel inva-
sion system (Becton Dickinson) following the protocol
provided by the manufacturer. 5 × 10
4 cells were seeded
on top of ECMatrix gel (Chemicon International, Inc.,
Temecula, CA). Cells were then incubated at 37°C for 6
h with or without HBO. Three different phase-contrast
microscopic high-power fields per well were photo-
graphed. The migratory cells with positive stain were
counted and the observer was blind to the experiment.
Glucose uptake in cultured human CAECs
Human CAECs were seeded on ViewPlate for 60 min
(Packard Instrument Co., Meriden, CT) at a cell density
of 5 × 10
3 cells/well in serum free medium for over-
night. Recombinant human visfatin 100 ng/ml (Adipo-
Gen, Inc., Incheon, Korea), visfatin siRNA, TNF-a
antibody, or TNF-a was added to the medium. Glucose
uptake was performed by adding 0.1 mmol/l 2-deoxy-D-
glucose and 3.33 nCi/ml 2-[1,2-
3H]-deoxy-D-glucose for
various periods of time. Cells were washed with phos-
phate-buffered saline twice. Non-specific uptake was
performed in the presence of 10 μM cytochalasin B and
subtracted from all of the measured value. MicroScint-
20 50 μl was added and the plate was read with Top-
Count (Packard Instrument Co., Meriden, CT). The
radioactivity was counted and normalized to protein
amount measured with a protein assay kit.
Statistical analysis
The data were expressed as mean ± SD. Statistical signifi-
cance was performed with analysis of variance (GraphPad
Software Inc., San Diego, CA). Tukey-Kramer comparison
test was used for pairwise comparisons between multiple
groups after the ANOVA. A value of P < 0.05 was consid-
ered to denote statistical significance.
Results
HBO increases visfatin expression
To investigate the effect of HBO on the expression of
visfatin protein, different degrees of ATA were used. As
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induced by HBO at 1.5, 2, and 2.5 ATA for 6 h. Since
2.5 ATA provided most powerful induction of visfatin
protein. The following experiments used 2.5 ATA as the
hyperbaric stimulation. The oxygen saturation measured
by Oxy-Check (HANNA Instruments, Inc., Woonsocket,
WI) and pO2 measured by pHOx Plus C (Nova Biome-
dical, Waltham, MA) in the medium was 523% and
>800 mmHg, respectively after HBO treatment for 6 h
and 77% and 175 mmHg, respectively in the control
without HBO treatment. The levels of visfatin protein
shown by Western blot analysis significantly increased
at 4 and 6 h after HBO treatment (Figure 2A and 2B) as
compared to control without treatment. Although visfa-
tin protein level still maintained elevated after 8 h of
HBO treatment, the level of visfatin protein tended to
return to baseline level. Visfatin mRNA significantly
increased at 2 h after HBO treatment, increased to max-
imal at 4 h and returned to baseline level at 8 h after
HBO treatment (Figure 2C). Because visfatin protein
was maximally induced at 6 h after HBO treatment, the
following experiments were set for HBO treatment for 6
hours. To simulate the clinical application of HBO,
HBO was also applied intermittently and repeatedly day
by day at 1 h per day. The visfatin protein level
increased by intermittent and repeat exposure was simi-
lar to that by 6 hr HBO exposure (Additional file 2,
Figure S2)
HBO-induced visfatin protein expression in human CAECs
is mediated by JNK kinase
As shown in Figure 3A and 3B, the Western blot
demonstrated that the HBO-induced increase of visfatin
protein was significantly reduced after the addition of
SB203580, and SP600125, 30 min before HBO treat-
ment. The addition of PD98059 and wortmannin did
not inhibit the visfatin protein expression induced by
H B O .T h e s ef i n d i n g si m p l i c a t e dt h a tJ N Ka n dE R K
pathways but not p38 MAP kinase and PI-3 kinase
mediated the induction of visfatin protein by HBO in
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visfatin protein expression most significantly. We then
focused on the JNK kinase pathway on the visfatin
protein expression induced by HBO. HBO at 2.5ATA
significantly increased the phosphorylation of JNK
(Figure 3C and 3D). SP600125, inhibitor of JNK kinase,
significantly attenuated the increased phosphorylation of
J N Ki n d u c e db yH B O .J N Ks i R N As i g n i f i c a n t l ya t t e n u -
ated the expression of phosphor-JNK induced by HBO.
The scrambled siRNA did not affect the phosphorylation
of JNK induced by HBO.
HBO-induced visfatin protein expression in human CAECs
is mediated by TNF-a
Exogenous addition of TNF-a at 300 pg/ml significantly
increased visfatin protein expression, similar to the level
i n d u c e db yH B Oa t2 . 5A T A( F i g u r e4 ) .E x o g e n o u s
addition of angiotensin II at 10 nM also increased visfa-
tin expression but the increased level was less than that
induced by TNF- a. Exogenous addition of IL-6 at 10
μg/ml did not increase visfatin expression. As shown in
Figure 5A, HBO at 2.5 ATA significantly began to
increase the TNF-a secretion from human CAECs at
2 h after HBO stimulation and remained elevated for 6 h
and then returned to baseline level after 8 h. The HBO-
induced vifatin protein expression was significantly atte-
nuated by the addition of TNF-a antibody (5 μg/mL) or
TNF-a receptor antibody (5 μg/mL). Addition of control
IgG did not abolish the induction of visfatin protein by
HBO. Exogenous addition of TNF-a at 300 pg/ml also
induced the visfatin protein expression (Figure 5B and
5C). These data indicate that TNF-a mediates the induc-
tion of visfatin protein expression by HBO. JNK siRNA
but not control siRNA significantly inhibited the visfatin
expression induced by TNF-a
HBO increases AP1-binding activity and visfatin promoter
activity
Treatment of HBO for 2 h to 6 h significantly increased
the DNA-protein binding activity of AP-1 (Figure 6A).
An excess of unlabeled AP-1 oligonucleotide competed
with the probe for binding AP-1 protein, whereas an oli-
gonucleotide containing a 2-bp substitution in the AP-1
binding site did not compete for binding. Addition of
SP600125 and TNF-a monoclonal antibody 30 min
before HBO stimulation abolished the DNA-protein
binding activity induced by HBO. Exogenous addition of
TNF-a significantly increased the DNA-protein binding
activity. To study whether the visfatin expression
induced by HBO is regulated at the transcriptional level,
we cloned the promoter region of human visfatin
(-889~+16), and constructed a luciferase reporter plas-
mid (pGL3-Luc). The visfatin promoter construct con-
tains AP-1, HIF-1a, and Stat-4 binding sites. As shown
in Figure 6B and 6C, transient transfection experiment
in human CAECs using this reporter gene revealed that
HBO for 6 h significantly induced visfatin promoter
activation. This result indicates that visfatin expression
is induced at transcriptional level by HBO. When the
AP-1 binding sites were mutated, the increased promo-
ter activity induced by HBO was abolished. Moreover,
addition of SP600125 and TNF-a antibody caused an
inhibition of transcription. The increased promoter
activity induced by exogenous addition of TNF-a was
similar to that induced by HBO at 2.5 ATA. These
results suggested that AP-1 binding site in the visfatin
promoter is essential for the transcriptional regulation
by HBO and that HBO regulates visfatin promoter via
TNF-a and JNK pathways.
Recombinant visfatin and HBO increase glucose uptake
HBO and recombinant human visfatin at 100 ng/ml sig-
nificantly increased glucose uptake at various periods of
incubation as compared to control human CAECs with-
out treatment (Figure 7). The glucose uptake in HBO-
treated cells was similar to that in exogenous addition
of visfatin and TNF-a. Addition of visfatin siRNA or
TNF-a antibody before HBO treatment attenuated the
glucose uptake to baseline levels.
HBO increases human CAECs tube formation and
migration
To test the effect of HBO on the function of human
CAECs, tube formation and migration activity was
examined. As shown in Figure 8, HBO for 6 h signifi-
cantly increased the tube formation of human CAECs.
Pretreatment with SP600125, TNF-a monoclonal anti-
body, and visfatin siRNA significantly blocked the induc-
tion of tube formation by HBO. The control siRNA did
not inhibit the tube formation induced by HBO. HBO
for 6 h significantly increased the migration activity of
human CAECs (Figure 9). Pretreatment with SP600125,
TNF-a monoclonal antibody, and visfatin siRNA signifi-
cantly blocked the induction of migration by HBO. The
control siRNA did not inhibit the migration induced by
HBO.
Discussion
In this study, we demonstrated several significant find-
ings. Firstly, HBO induces transient visfatin expression in
cultured human CAECs in a time- and load-dependent
manner. Secondly, TNF-a a c t sa sa na u t o c r i n ef a c t o rt o
mediate HBO-induced visfati np r o t e i ne x p r e s s i o ni n
human CAECs. Thirdly, JNK kinase and AP-1 transcrip-
tion factor are involved in the signaling pathways of visfa-
tin induction by HBO. Fourthly, HBO increases tube
formation and migration activity of human CAECs. The
findings that HBO induces visfatin expression in human
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and migration increase by HBO may further strengthen
the effect of HBO on angiogenesis. In addition to insulin-
mimetic effect, visfatin has been shown to induce angio-
genesis via fibroblast growth factor, STAT-3 and vascular
endothelial growth factor [6-8]. Recently, Adyaet al also
reported that visfatin induces angiognesis via monocyte-
chemoattractant protein-1 in human endothelial cells
[17]. Our study confirmed the effect of angiogenesis of
visfatin on human CAECs after HBO treatment.
Visfatin is a cytokine with various functions [12].
Recently, visfatin was shown to induce inflammatory
cytokines expression in human endothelial cells and
then caused endothelial dysfunction [18]. However, Lim
et al. demonstrated cardio-protective effect of visfatin
which is capable of reducing myocardial injury when
administered at the time of myocardial reperfusion [19].
Our study demonstrated that HBO induced secretion of
TNF-a, an inflammatory cytokine, from human CAECs
and TNF-a increased visfatin expression by autocrine
mechanism because exogenous administration of TNF-a
also enhanced visfatin expression and TNF-a and TNF-a
receptor antibody attenuated the increase of visfatin by
HBO. AP-1 is a principal transcriptional factor that is acti-
vated by TNF-a and AP-1 is a well-characterized down-
stream target of JNK. In this study, we demonstrated that
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oligonucleotide in nuclear extracts of human CAECs after HBO treatment in the presence or absence of inhibitors and TNF-a antibody. Similar
results were found in another two independent experiments. Cold oligo means unlabeled AP-1 oligonucleotides. B, Constructs of visfatin
promoter gene. Positive +1 demonstrates the initiation site for the visfatin transcription. Mutant visfatin promoter indicates mutation of AP-1
binding sites in the visfatin promoter as indicated. C, Quantitative analysis of visfatin promoter activity. The luciferase activity in cell lysates was
measured and was normalized with renilla activity (n = 4 per group). *P < 0.001 vs. control.
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Page 10 of 14HBO increased AP-1 binding activity. TNF-a antibody
and SP600125 inhibited the AP-1 binding activity induced
by HBO, indicating that TNF-a and JNK pathway mediate
the increased transcriptional activity of AP-1 in the HBO
model. Furthermore, TNF-a antibody and SP600125 atte-
nuated the promoter activity of visfatin by HBO. Our data
also indicate that AP-1 binding site in the visfatin promo-
ter is essential for the transcriptional regulation by HBO
because a mutant AP-1 binding site in the visfatin promo-
ter abolished the transcriptional activity induced by HBO.
We have used three proinflammatory cytokines to sti-
mulate human CAECs. Interleukin-6 did not have any
effect on visfatin release and angiotensin II had partial
effect on visfatin release. TNF-a produced most potent
effect on visfatin release. Storka et al. have demonstrated
no effect of angiotensin II on the release of visfatin from
human umbilical vein endothelial cells, adipocytes and
skeletal muscle cells [20]. The discrepancy result may
indicate different cell types respond differently to pro-
inflammatory cytokine stimulation to release visfatin.
Endothelial progenitor cell mobilization, homing and
wound healing were enhanced by HBO through nitric
oxide pathway [21-23]. However, the direct effect of
HBO on human CAECs has not reported yet. In this
study, we investigated the direct effect of HBO on
human CAECs and demonstrated that HBO enhanced
visfatin expression. HBO may induce different genes
expression in different cell types via different signal
pathways [24,25]. Hyperoxia with 100% oxygen has been
shown to generate reactive oxygen species and produce
vasoconstriction of coronary artery [26]. HBO is different
with hyperoxia because hyperoxia is administered with
normal baric pressure. The use of hyperbaric pressure of
oxygen makes HBO a safe and noninvasive modality for
the treatment of many kinds of diseases. In this study,
HBO induces tube formation of human CAECs, an
essential part for angiogenesis, indicating that HBO may
be applied for patients with refractory ischemic heart dis-
eases with non-optional therapy. In the study, HBO also
significantly increased formation of reactive oxygen spe-
cies for 2 to 8 h (Additional file 3, Figure S3). This result
may suggest that HBO for 2-8 h causes oxygen toxicity.
In the present study, a protocol of 2.5 ATA 6 h HBO
is definitely not a “treatment” protocol. In the clinical
treatment protocol, HBO is applied intermittently and
repeatedly day by day at 1 h per day. Prolonged expo-
sure to HBO causes significantly toxicity effects to the
neurologic system as well as to any cultured cells. The
visfatin induced by HBO in our study protocol may be
caused by oxygen toxicity. In the present study, we
found that HBO for 6 h increased human CAECs migra-
tion and proliferation, an early process of angiogenesis.
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Figure 7 Effect of HBO and recombinant visfatin on glucose uptake in human CAECs. Glucose uptake was measured in human CAECs
treated for 90 min with 100 ng/ml recombinant visfatin with or without siRNA, TNF-a, or TNF-a antibody (Ab). *P < 0.01 vs. control;
#P < 0.001
vs. HBO. Data are from 4 independent experiments.
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Page 11 of 14Exogenous addition of visfatin also increased migration
of human CAECs without HBO stimulation (Additional
file 4, Figure S4). Visfatin siRNA attenuated the migra-
tion and proliferation of human CAECs induced by
HBO. MTT assay did not show significant cytotoxicity
of HBO on human CAECs as compared to control or
visfatin treatment (Additional file 4, Figure S4). The
increased visfatin induced by HBO to increase angiogen-
esis may counteract the oxygen toxicity by prolonged
HBO exposure.
Visfatin has been demonstrated to mimic the glucose-
lowering effect of insulin and improve insulin sensitivity
[3]. In this study, we have demonstrated that HBO
increases glucose uptake in human CAECs, similar to
the effect of visfatin. Visfatin siRNA attenuated the glu-
cose uptake by HBO. This finding indicates that visfatin
mediates the glucose uptake by HBO in human CAECs.
G l u c o s eu p t a k ei n c r e a s eb yH B Om a yi m p r o v et h e
energy metabolism in CAECs which may provide myo-
cardial protection and anti-ischemic effect.
Conclusions
Our study reports for the first time that HBO enhances
visfatin expression in cultured human CAECs. The
HBO-induced visfatin is mediated by TNF-a and at
least in part through JNK pathway. Visfatin increases
angiogenesis after HBO, indicating that visfatin counter-
acts the oxygen toxicity by HBO.
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Figure 8 Effect of HBO on human CAECs tube formation. A, Representative image of tube formation of human CAECs. B, Quantitative tube
length measurement (n = 5). *P < 0.001 vs. HBO alone.
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Additional file 1: Figure S1: Schematic diagram of hyperbaric
chamber in incubator.
Additional file 2: Figure S2: Effect of intermittent and repeat HBO
exposure on visfatin protein expression. HBO at 2.5 ATA was applied
1 h per day. A, Representative Western blot for visfatin in human CAECs
treated with HBO at 1 h each day for different duration. B, Quantitative
analysis of visfatin protein levels (n = 4 per group). *P < 0.05 vs. control.
**P < 0.001 vs. control.
Additional file 3: Figure S3: Effect of HBO on reactive oxygen
species (ROS) formation in human CAECs. A, Representative
microscopic image for ROS assay with (left panel) or without green
fluorescence (right panel). B, Quantitative analysis of the positive
fluorescent cells. Control group indicates normoxia group. (n = 4 per
group). *P < 0.05 vs. control. **P < 0.01 vs. control.
Additional file 4: Figure S4: Effect of recombinant visfatin on
migration and viability of human CAECs. A, Representative image of
migration of human CAECs. B, Quantitative migration activity
measurement (n = 4). *P < 0.001 vs. control. C, Quantitative analysis of
viability by MTT assay.
List of abbreviations used
AP-1: activating protein-1; CAECs: coronary artery endothelial cells; ERK:
extracellular-signal-regulated kinase; EMSA: electrophoretic mobility shift
assay; HBO: hyperbaric oxygen; JNK: c-Jun N-terminal kinase; siRNA: small
interfering RNA; TNF-α: tumor necrosis factor-α; TLR: toll-like receptor; TNF-α:
tumor necrosis factor-α.
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